BioSpace News Archive

Bolt Biotherapeutics, Inc. today announced that it will be presenting a poster at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting, being held at McCormick Place in Chicago and virtually from June 3-7, 2022.

Mercy Halo Data Demonstrates Promise of Novel Extracellular Vesicle Biomarker-Based Approach for Early Cancer Detection.

Catalent, the global leader in enabling biopharma, cell, gene, and consumer health partners to optimize development, launch, and supply of better patient treatments across multiple modalities, today announced that members of its executive leadership team will present at two upcoming investor conferences.

VistaGen will present at upcoming William Blair 42 nd Annual Growth Stock Conference and Jefferies Global Healthcare Conference.

Exact Sciences Corp. (NASDAQ: EXAS), a leader in advanced cancer diagnostics, today announced new data supporting its cancer tests and treatment guidance tools will be showcased in nine poster presentations and five e-abstracts at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting, being held June 3-7 in Chicago.

QuidelOrtho Corporation (NASDAQ: QDEL) (“QuidelOrtho”) announced completion of the transaction combining Quidel Corporation (“Quidel”) and Ortho Clinical Diagnostics Holdings plc (“Ortho”), creating QuidelOrtho, a leading in vitro diagnostics company.

LintonPharm Co., Ltd., a China-based biopharmaceutical company focusing on the development of T cell engaging bispecific antibodies for cancer immunotherapy, announces that preliminary results of Catumaxomab for advanced Gastric Cancer (GC) with peritoneal metastasis is published online at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting.

The first patients have been dosed in the IRIS Phase III clinical trial of anifrolumab in lupus nephritis (LN).

SciSparc Ltd. today announced that it entered into a securities purchase agreement with a single healthcare-focused institutional investor for aggregate gross proceeds of approximately $10 million, before deducting fees to the placement agent and other offerings expenses.

Kintara Therapeutics, Inc. (Nasdaq: KTRA) (“Kintara” or the “Company”), today announced that the VAL-083 treatment arm in the Global Coalition for Adaptive Research (GCAR) registrational Phase 2/3 clinical trial for glioblastoma (GBM), titled Glioblastoma Adaptive Global Innovative Learning Environment (GBM AGILE), has activated its first European site, University Hospital Zurich in Zurich, Switzerland.